Chemical Business Newsbase articles from July 2009, page 2

Chemical Business Newsbase archives from July 2009

Genentech signs contract with Bayhill for new diabetes drug.
July 31, 2009... US company Genentech signed a new licence agreement with US company Bayhill Therapeutics in San Mateo, CA for the development of a new treatment for the early stages of type 1 diabetes. Bayhill will receive an advance payment of $25 M and stands...

Sika 1H 2009: Sika shows fortitude in a tough market environment. [1 table in original article].
July 31, 2009... Sika reported a 12.3% decline in group sales during 1H 2009 to SFR 1.9829 bn, and a 31.1% fall in EBITDA to SFR 214 M. EBIT was down 40.8% at SFR 148.3 M and net profits were down 43.4% at SFR 92.1 M. Profits per share were down 43% at SFR 37.1...

Novus Kazakhstan now open for business.
July 31, 2009... Novus Sealing's Kazakhstan office is now fully operational. The new venture, based in Atyrau, has manufacturing capabilities, and has been set up to service the country's highly productive oil companies. The new office will now be supplying its...

Novus Sealing continues global expansion.
July 31, 2009... Despite the difficulties posed by the global downturn, Novus Sealing continues to deliver improvements in its range of services and product lines. With new facilities now established in Kazakhstan and the Middle East, and expansion of the...

Ajinomoto to expand osteoporosis treatment risedronate business in Japan by obtaining related assets including patents and trademarks from P&G.
July 31, 2009... On 31 Jul 2009, Ajinomoto Co Inc signed an agreement with The Procter & Gamble Co and Procter & Gamble Pharmaceuticals Inc for the transfer of P&G assets relating to the business of an osteoporosis treatment risedronate (generic...

Metaldehyde limits.
July 31, 2009... An independent crop consultant has advised growers planning to follow potato crops with winter wheat to plan in advance so as to avoid going beyond the new maximum metaldehyde rates of 700 g/ha/calendar year. New guidelines on metaldehyde limit...

Global Fund reaffirms commitment to Uganda.
July 31, 2009... The Global Fund to Fight AIDS, Tuberculosis and Malaria said that it is committed to working with the government and other partners in Uganda to accelerate the implementation of Global Fund-supported HIV, tuberculosis and malaria programs. "We...

Eliokem India announces price increase from 8-15% on various Chemigum NBR and Pliolite HSR grades, effective August 1st 2009.
July 31, 2009... Eliokem India announces price increase from 8 to 15 % on various Chemigum NBR and Pliolite HSR grades, effective 1 Aug 2009. This increase is due to substantial increases in raw material prices. Monomer prices have been volatile and this...

UCB half year report 2009: UCB progress: new product launches and financials on track: financial performance in 1H 2009.
July 31, 2009... In 1H 2009 new product launches partially compensated for the impact of generic competition to Keppra (levetiracetam) in the US. UCB's total revenue decreased as expected by 6% to EUR 1 596 M. Net sales amounted to EUR 1 379 M (-10% lower...

UCB half year report 2009: UCB progress: new product launches and financials on track: outlook 2009 confirmed.
July 31, 2009... UCB's 2009 full year revenue is expected to reach between EUR 3.1-3.3 bn. Underlying profitability (recurring EBITDA) is expected to exceed EUR 680 M and net profit to increase to EUR 550 M

UCB half year report 2009: UCB progress: new product launches and financials on track: research and development update.
July 31, 2009... UCB's collaboration with Amgen to develop CDP7851 sclerostin antibody (a novel anabolic therapy for bone loss disorders) is progressing. Following encouraging first-in-human data, in Jun 2009 UCB and Amgen initiated a Phase II study in...

Honeywell declares quarterly dividend payable on 10 Sep 2009.
July 31, 2009... The board of directors of Honeywell International Inc has declared a regular quarterly dividend of $0.3025/share on the company's outstanding common stock. The dividend is payable on 10 Sep 2009 to shareowners of record at the close of business...

Revision of earnings forecasts.
July 31, 2009... Daiichi Sankyo Co Ltd announced on 31 Jul 2009 a revision of its earnings forecasts which was announced on 12 May 2009 in light of recent trends in operating performance. Projected net sales remain the same at Yen 465,000 M, while operating...

Daiichi Sankyo establishes new department for vaccine business.
July 31, 2009... Daiichi Sankyo Co Ltd announced on 31 Jul 2009 the launch of "Vaccine Business Planning Department" as of 1 Oct 2009 to further enhance its vaccine business. Medical needs for vaccines have been increasing more than ever, following the increased...

Daiichi Sankyo reaches agreement to transfer Shizuoka plant to CMIC.
July 31, 2009... Daiichi Sankyo came to a basic agreement with CMIC Co Ltd on 31 Jul 2009 regarding the transfer of the Shizuoka plant of its subsidiary Daiichi Sankyo Propharma. The Daiichi Sankyo Group is working to expand its growth platform to meet its...

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: Results of operations.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), Sumitomo Chemical Co Ltd has reported net sales of Yen 340.7 bn (Yen 496.3 bn for its 1Q 2008), operating income of Yen 2303 M (Yen 24.6 bn), ordinary income of Yen 3205 M (Yen 25.3 bn), and a net loss...

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: Basic Chemicals.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Basic Chemicals business segment of Sumitomo Chemical Co Ltd has reported net sales of Yen 42.4 bn (Yen 75.6 bn for its 1Q 2008) and an operating loss of Yen 2843 M (operating income of Yen 1589 M)....

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: Petrochemicals and Plastics.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Petrochemicals and Plastics business segment of Sumitomo Chemical Co Ltd has reported net sales of Yen 96.1 bn (Yen 164.8 bn for its 1Q 2008) and an operating loss of Yen 5620 M (operating loss of...

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: Fine Chemicals.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Fine Chemicals business segment of Sumitomo Chemical Co Ltd has reported net sales of Yen 14.7 bn (Yen 24.3 bn for its 1Q 2008) and an operating loss of Yen 108 M (operating income of Yen 1253 M)....

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: Agricultural Chemicals.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Agricultural Chemicals business segment of Sumitomo Chemical Co Ltd has reported net sales of Yen 54.2 bn (Yen 54.2 bn for its 1Q 2008) and operating income of Yen 5809 M (Yen 5794 M). Sales of feed...

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: Pharmaceuticals.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Pharmaceuticals business segment of Sumitomo Chemical Co Ltd has reported net sales of Yen 59.4 bn (Yen 62.9 bn for its 1Q 2008) and operating income of Yen 9774 M (Yen 11.0 bn). Sales of Amlodin...

Mitsui Chemicals 2008-2009: Financial Highlights.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), Mitsui Chemicals Inc has reported net sales of Yen 1487.6 bn (Yen 1786.6 bn for its fiscal 2007), an operating loss of Yen 45.4 bn (operating income of Yen 77.1 bn), a net loss of Yen 95.2 bn (net...

Mitsui Chemicals 2008-2009: R&D Sustaining Corporate Social Responsibility "(CSR) through our main businesses".
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), Mitsui Chemicals Inc has reported R&D expenditure of Yen 40.6 bn (Yen 42.1 bn for its fiscal 2008), of which: corporate R&D accounted for Yen 40.6 bn, strategic R&D Yen 3.7 bn,...

Mitsui Chemicals 2008-2009: Performance Materials.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Performance Materials division of Mitsui Chemicals Inc has reported net sales of Yen 431.8 bn (Yen 504.0 bn for its fiscal 2007), an operating loss of Yen 16.0 bn (operating income of Yen 35.8...

Mitsui Chemicals 2008-2009: Advanced Chemicals.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Advanced Chemicals division of Mitsui Chemicals Inc has reported net sales of Yen 118.6 bn (Yen 122.1 bn for its fiscal 2007), operating income of Yen 7311 M (Yen 10.7 bn), capital expenditure...

Mitsui Chemicals 2008-2009: Basic Chemicals.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Basic Chemicals division of Mitsui Chemicals Inc has reported net sales of Yen 912.7 bn (Yen 1111.1 bn for its fiscal 2007), an operating loss of Yen 32.0 bn (operating income of Yen 33.4 bn),...

Mitsui Chemicals 2008-2009: Intellectual property strategy.
July 31, 2009... The Intellectual Property Division, of Mitsui Chemicals Inc, is dedicated to developing and implementing strategies to achieve "management objectives focusing on the three dimensions of 'economy', 'environment' and 'society'" and "creation of...

Mitsui Chemicals 2008-2009: Geographic distribution: Japan.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), Mitsui Chemicals Inc has reported net sales in Japan of Yen 1266.8 bn (Yen 1536.2 bn for its fiscal 2007) and an operating loss of Yen 41.4 bn (operating income of Yen 72.0 bn). Despite successful...

Mitsui Chemicals 2008-2009: Geographic distribution: Asia.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), Mitsui Chemicals Inc has reported net sales in Asia of Yen 255.6 bn (Yen 317.8 bn for its fiscal 2007) and an operating loss of Yen 3186 M (operating income of Yen 1165 M). Mitsui Phenols Singapore...

Mitsui Chemicals 2008-2009: Geographic distribution: Others.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), Mitsui Chemicals Inc has reported net sales in its "Others" region of Yen 97.1 bn (Yen 106.2 bn for its fiscal 2007) and an operating loss of Yen 891 M (operating income of Yen 3936 M). In the US, a...

Mitsui Chemicals 2008-2009: Capital expenditures.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), Mitsui Chemicals Inc has reported capital expenditure of Yen 81. 0 bn (Yen 84.6 bn for its fiscal 2008). This amount includes expenditures on intangible fixed assets as well as long-term prepaid...

Rhodia financial report half-year ended 30 Jun 2009: Consolidated statement of income.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), Rhodia SA has reported net sales of EUR 1907 M (EUR 2413 M for its 1H 2008), R&D expenditure of EUR 33 M (EUR 37 M), an operating loss of EUR 53 M (operating income of EUR 208 M), a net loss of EUR...

Rhodia financial report half-year ended 30 Jun 2009: Novecare.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Novecare division of Rhodia SA has reported net sales of EUR 417 M (-12.2% on its 1H 2008) and operating profit of EUR 10 M (EUR 40 M). The positive currency conversion impact of 6.5% mainly...

Rhodia financial report half-year ended 30 Jun 2009: Silcea.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Silcea division of Rhodia SA has reported net sales of EUR 291 M (-24.2% on its 1H 2008) and an operating loss of EUR 5 M (operating profit of EUR 41 M). Changes in conversion rates, essentially due...

Rhodia financial report half-year ended 30 Jun 2009: Energy Services.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Energy Services division of Rhodia SA has reported net sales of EUR 92 M (-11.5% on its 1H 2008) and operating profit of EUR 74 M (EUR 86 M). The sales total is essentially the result of income from...

Rhodia financial report half-year ended 30 Jun 2009: Eco Services.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Eco Services division of Rhodia SA has reported net sales of EUR 121 M (-4.7% on its 1H 2008) and operating profit of EUR 35 M (EUR 26 M). Eco Services operates exclusively in the US. Changes in...

Mitsui Chemicals financial summary 1Q FY 2009: Consolidated financial highlights.
July 31, 2009... For its 1Q 2009, Mitsui Chemicals Inc has reported sales of Yen 260.6 bn (Yen 453.9 bn for its 1Q 2008), of which: Performance Materials accounted for Yen 80.1 bn (Yen 126.3 bn), Advanced Chemicals Yen 24.5 bn (Yen 31.4 bn), and Basic Chemicals...

Sumitomo Chemical reports consolidated financial results for the three months ended 30 Jun 2009: IT-Related Chemicals.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the IT-Related Chemicals business segment of Sumitomo Chemical Co Ltd has reported net sales of Yen 45.9 bn (Yen 77.8 bn for its 1Q 2008) and an operating loss of Yen 3123 M (operating income of Yen...

Taisho Pharmaceutical consolidated financial statements for the first three months of the 31 Mar 2010 fiscal year: Consolidated operating results.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), Taisho Pharmaceutical Co Ltd has reported net sales of Yen 63.5 bn (Yen 61.8 bn for its 1Q 2008), operating income of Yen 6256 M (Yen 11.6 bn), ordinary income of Yen 7074 M (Yen 12.3 bn), net income of...

Taisho Pharmaceutical consolidated financial statements for the first three months of the 31 Mar 2010 fiscal year: Self-Medication Operations Group.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Self-Medication Operations Group of Taisho Pharmaceutical Co Ltd has reported net sales of Yen 38.56 bn (Yen 38.64 bn for its 1Q 2008) and operating income of Yen 6516 M (Yen 8863 M). With regard to...

Taisho Pharmaceutical consolidated financial statements for the first three months of the 31 Mar 2010 fiscal year: Prescription Pharmaceutical Operations Group.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Prescription Pharmaceutical Operations Group of Taisho Pharmaceutical Co Ltd has reported net sales of Yen 24.99 bn (Yen 23.20 bn for its 1Q 2008) an operating loss of Yen 259 M (operating income of...

Rhodia financial report half-year ended 30 Jun 2009: Polyamide.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Polyamide division of Rhodia SA has reported net sales of EUR 633 M (-34.8% on its 1H 2008) and an operating loss of EUR 153 M (operating profit of EUR 63 M). Changes in conversion rates generated a...

Rhodia financial report half-year ended 30 Jun 2009: Acetow.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Acetow division of Rhodia SA has reported net sales of EUR 275 M (+21.7% on its 1H 2008) and operating profit of EUR 52 M (EUR 23 M). Acetow enjoyed a satisfactory level of demand for the first half...

Kissei Pharmaceutical consolidated financial results for 1Q FY 03/2010: Financial highlights.
July 31, 2009... For its 1Q 2010 (period ends 30 Jun 2009), Kissei Pharmaceutical Co Ltd has reported net sales of $164.3 M ($158.3 M for its 1Q 2009), gross profit of $58.1 M ($52.8 M), operating profit of $17.6 M ($22.0 M), and net profit of $12.9 M ($15.4 M).

Kissei Pharmaceutical consolidated financial results for 1Q FY 03/2010: trends in main product sales.
July 31, 2009... For its 1Q 2010 (period ends 30 Jun 2009), Kissei Pharmaceutical Co Ltd has reported product sales data: Urief Yen 2071 M (Yen 1312 M for its 2Q 2009), Glufast Yen 1144 M (Yen 931 M), Salagen Yen 195 M (Yen 148 M), Bezatol Yen 2188 M (Yen 2191...

Mitsubishi Chemical Holdings consolidated financial information for 1Q of the fiscal year ending 31 Mar 2010: results of operations.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), Mitsubishi Chemical Holdings Corp has reported net sales of Yen 549.7 bn (Yen 763.7 bn for its 1Q 2008), an operating loss of Yen 10.6 bn (operating income of Yen 34.5 bn), a net loss of Yen 16.7 bn...

Mitsubishi Chemical Holdings consolidated financial information for 1Q of the fiscal year ending 31 Mar 2010: Electronics Applications segment, Performance Products domain.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Electronics Applications business segment Mitsubishi Chemical Holdings Corp has reported net sales of Yen 66.7 bn (Yen 92.3 bn for its 1Q 2008) and an operating loss of Yen 921 M (operating income...

Mitsubishi Chemical Holdings consolidated financial information for 1Q of the fiscal year ending 31 Mar 2010: Designed Materials segment, Performance Products domain.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Designed Materials business segment Mitsubishi Chemical Holdings Corp has reported net sales of Yen 57.3 bn (Yen 69.7 bn for its 1Q 2008) and an operating loss of Yen 816 M (operating income of Yen...

Mitsubishi Chemical Holdings consolidated financial information for 1Q of the fiscal year ending 31 Mar 2010: Health Care segment, Health Care domain.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Health Care business segment Mitsubishi Chemical Holdings Corp has reported net sales of Yen 126.5 bn (Yen 128.3 bn for its 1Q 2008) and operating income of Yen 25.1 bn (Yen 26.6 bn). Main products...

Mitsubishi Chemical Holdings consolidated financial information for 1Q of the fiscal year ending 31 Mar 2010: Chemicals segment, Chemicals domain.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Chemicals business segment Mitsubishi Chemical Holdings Corp has reported net sales of Yen 174.2 bn (Yen 281.5 bn for its 1Q 2008) and an operating loss of Yen 2904 M (operating income of Yen 2424...

Mitsubishi Chemical Holdings consolidated financial information for 1Q of the fiscal year ending 31 Mar 2010: Polymers segment, Chemicals domain.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), the Polymers business segment Mitsubishi Chemical Holdings Corp has reported net sales of Yen 92.0 bn (Yen 155.2 bn for its 1Q 2008) and an operating loss of Yen 28.1 bn (operating income of Yen 1049...

Schwarz Pharma half-year report 2009: Key figures overview.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), Schwarz Pharma AG has reported revenues of EUR 208.0 M (EUR 191.8 M for its 1H 2008), R&D expenditure of EUR 27.9 M (EUR 52.1 M), operating income of EUR 106.4 M (operating loss of EUR 15.0 M), and...

Schwarz Pharma half-year report 2009: Geographic segment reporting.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), Schwarz Pharma AG has reported revenues of EUR 208.0 M (EUR 191.8 M for its 1H 2008), of which: Germany accounted for EUR 83.8 M (+12.5%), Europe & rest of world EUR 56.3 M (-16.3%), Commonwealth of...

Schwarz Pharma half-year report 2009: Discontinued Operations.
July 31, 2009... As part of the company's continued integration into the UCB group, the following Schwarz Pharma affiliates were already transferred to a UCB group company as per 31 Dec 2008: Schwarz Pharma Korea Co Ltd, South Korea and Schwarz Pharma MEPE,...

Showa Denko 2Q 2009 financial results (consolidated): Consolidated sales by segment (6 months cumulative period): Inorganics.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Inorganics segment of Showa Denko KK has reported net sales of Yen 22.9 bn (Yen 43.5 bn for its 1H 2008), operating income of Yen 0.3 bn (Yen 9.8 bn), and capital expenditure of Yen 2.0 bn (Yen 1.3...

Showa Denko 2Q 2009 financial results (consolidated): Consolidated sales by segment (6 months cumulative period): Aluminium.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Aluminium segment of Showa Denko KK has reported net sales of Yen 77.7 bn (Yen 120.8 bn for its 1H 2008), an operating loss of Yen 6.8 bn (operating income of Yen 0.7 bn), and capital expenditure of...

Schwarz Pharma half-year report 2009: Product sales.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), Schwarz Pharma AG has reported drug sales revenues of EUR 166.8 M (EUR 177.5 M for its 1H 2008), of which: Atmadisc accounted for EUR 30.8 M (EUR 28.7 M), Edex/Prostavasin EUR 24.0 M (EUR 29.6 M),...

Schwarz Pharma half-year report 2009: R&D: Neupro once again available to all patients in Europe.
July 31, 2009... In May 2009, the European Medicines Agency (EMEA) submitted a recommendation to the European Commission for lifting the restrictions on Neupro (rotigotine transdermal patch) for treating Parkinson's disease and Restless Legs Syndrome (RLS). The...

Showa Denko 2Q 2009 financial results (consolidated): Summary (6 months cumulative period).
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), Showa Denko KK has reported net sales of Yen 286.7 bn (Yen 510.8 bn for its 1H 2008), an operating loss of Yen 22.9 bn (operating income of Yen 24.6 bn), an ordinary loss of Yen 34.3 bn (ordinary income...

Showa Denko 2Q 2009 financial results (consolidated): Consolidated sales by segment (6 months cumulative period): Petrochemicals.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Petrochemicals segment of Showa Denko KK has reported net sales of Yen 96.2 bn (Yen 204.7 bn for its 1H 2008), operating income of Yen 2.0 bn (Yen 6.0 bn), and capital expenditure of Yen 2.8 bn (Yen...

Showa Denko 2Q 2009 financial results (consolidated): Consolidated sales by segment (6 months cumulative period): Chemicals.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Chemicals segment of Showa Denko KK has reported net sales of Yen 46.8 bn (Yen 40.8 bn for its 1H 2008), an operating loss of Yen 1.1 bn (operating income of Yen 3.7 bn), and capital expenditure of...

Showa Denko 2Q 2009 financial results (consolidated): Consolidated sales by segment (6 months cumulative period): Electronics.
July 31, 2009... For its 1H 2009 (period ends 30 Jun 2009), the Electronics segment of Showa Denko KK has reported net sales of Yen 43.0 bn (Yen 101.1 bn for its 1H 2008), an operating loss of Yen 15.7 bn (operating income of Yen 7.5 bn), and capital expenditure...

DIC 2008-2009: Consolidated financial highlights.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), DIC Corp has reported net sales of Yen 923.3 bn (Yen 1077.8 bn for its fiscal 2008), operating income of Yen 25.3 bn (Yen 48.3 bn), net income of Yen 2648 M (Yen 31.0 bn), basic EPS of Yen 3.35 (Yen...

DIC 2008-2009: DIC announces domestic printing inks business integration: DIC Graphics Corp.
July 31, 2009... On 29 Jun 2009, DIC Corp announced that it had signed an agreement with a leading Japanese printing company Dai Nippon Printing Co Ltd (DNP) and DNP subsidiary The Inctec Inc to integrate the domestic printing inks businesses of DIC and the...

DIC 2008-2009: Graphic Arts Materials.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Graphic Arts Materials division of DIC Corp has reported net sales of Yen 574.6 bn (Yen 646.4 bn for its fiscal 2008), operating income of Yen 25.5 bn (Yen 34.3 bn), and capital expenditure of...

DIC 2008-2009: Graphic Arts Materials: Japan.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Japan segment of the Graphic Arts Materials division of DIC Corp has reported net sales of Yen 108.2 bn (-3.4% on its fiscal 2008), of which: printing inks accounted for Yen 91 M (Yen 92 M), and...

DIC 2008-2009: High Performance and Applied Products.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the High Performance and Applied Products division of DIC Corp has reported net sales of Yen 124.1 bn (Yen 131.3 bn for its fiscal 2008), operating income of Yen 1962 M (Yen 4630 M), and capital...

DIC 2008-2009: Electronics and Information Materials.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Electronics and Information Materials division of DIC Corp has reported net sales of Yen 44.3 bn (Yen 52.4 bn for its fiscal 2008), operating income of Yen 1466 M (Yen 6426 M), and capital...

DIC 2008-2009: Research and Development.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), DIC Corp has reported R&D expenditure of Yen 14.7 bn (Yen 15.5 bn for its fiscal 2008). There is detailed discussion of the company's R&D program, covering: overview, graphic arts materials...

DIC 2008-2009: Corporate social responsibility.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), DIC Corp has reported energy consumption of 102 M litres (crude oil equivalent) (117 M litres for its fiscal 2008), greenhouse gas emissions of 211,000 tonnes (239,000 tonnes), waste to landfill of...

DIC 2008-2009: Operations in different geographic areas.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), DIC Corp has reported net sales of Yen 923.3 bn (Yen 1077.8 bn for its fiscal 2008), of which: Japan accounted for Yen 407.2 bn (Yen 480.6 bn), the Americas Yen 164.6 bn (Yen 197.1 bn), Europe Yen...

DIC 2008-2009: Graphic Arts Materials: Asia and Oceania.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Asia and Oceania segment of the Graphic Arts Materials division of DIC Corp has reported net sales of Yen 69.0 bn (-3.1% on its fiscal 2008), of which: printing inks accounted for Yen 110 M (Yen...

DIC 2008-2009: Industrial Materials.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Industrial Materials division of DIC Corp has reported net sales of Yen 173.1 bn (Yen 197.5 bn for its fiscal 2008), operating income of Yen 5129 M (Yen 9977 M), and capital expenditure of Yen...

DIC 2008-2009: Graphic Arts Materials: The Americas and Europe.
July 31, 2009... For its fiscal 2009 (period ends 31 Mar 2009), the Americas and Europe segment of the Graphic Arts Materials division of DIC Corp has reported net sales of Yen 413.3 bn (-13.5% on its fiscal 2008), of which: printing inks accounted for Yen 94 M...

Ashland increases resin and gelcoat prices in India.
July 31, 2009... Ashland Performance Materials, a commercial unit of Ashland Inc, is increasing the price of its unsaturated polyester resins, vinyl ester resins and gelcoats produced and sold in India by 3-5% effective 1 Aug 2009, or at the earliest possible...

Newly adopted Marketing Authorisation Decisions (28 Jul 2009): Clopidogrel Acino.
July 31, 2009... On 31 Jul 2009 the European Commission (EC) announced decision number C(2009)6149 of 28 Jul 2009, the approval of EU/1/09/532 for Clopidogrel Acino. The product contains clopidogrel at 75mg (seven package sizes) and is indicated in adults for...

Newly adopted Marketing Authorisation Decisions (28 Jul 2009): Grepid.
July 31, 2009... On 31 Jul 2009 the European Commission (EC) announced decision number C(2009)6153 of 28 Jul 2009, the approval of EU/1/09/535 for Grepid. The product contains clopidogrel at 75mg (fourteen package sizes) and is indicated in adults for the...

Newly adopted Marketing Authorisation Decisions (28 Jul 2009): Clopidogrel Teva.
July 31, 2009... On 31 Jul 2009 the European Commission (EC) announced decision number C(2009)6154 of 28 Jul 2009, the approval of EU/1/09/540 for Clopidogrel Teva. The product contains clopidogrel at 75mg (nine items) and is indicated in adults for the...

Newly adopted Marketing Authorisation Decisions (28 Jul 2009): Clopidogrel ratiopharm GmbH.
July 31, 2009... On 31 Jul 2009 the European Commission (EC) announced decision number C(2009)6150 of 28 Jul 2009, the approval of EU/1/09/541 for Clopidogrel ratiopharm GmbH. The product contains clopidogrel at 75mg (seven package sizes) and is indicated in...

Newly adopted Marketing Authorisation Decisions (28 Jul 2009): Clopidogrel 1A Pharma.
July 31, 2009... On 31 Jul 2009 the European Commission (EC) announced decision number C(2009)6151 of 28 Jul 2009, the approval of EU/1/09/542 for Clopidogrel 1A Pharma. The product contains clopidogrel at 75mg (seven package sizes) and is indicated in adults...

Dainippon Sumitomo Pharma summary of consolidated financial results for the first quarter of the year ended 31 Mar 2010 (unaudited): results of operations.
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), Dainippon Sumitomo Pharma has reported net sales of Yen 66.0 bn (Yen 70.1 bn for its 1Q 2008), of which: pharmaceuticals accounted for Yen 52.0 bn (Yen 55.6 bn); operating income of Yen 11.2 bn (Yen...

Dainippon Sumitomo Pharma summary of consolidated financial results for the first quarter of the year ended 31 Mar 2010 (unaudited): Sales of major products: pharmaceuticals (domestic). [1 table in original article].
July 31, 2009... A full-page table shows sales data for Dainippon Sumitomo Pharma's twenty best-selling products, in its domestic market, for 1Q 2008 and 2009, including: Amlodin (amlodipine) Yen 13.6 bn (Yen 16.4 bn for its 1Q 2008), lonansen (blonanserin) Yen...

Dainippon Sumitomo Pharma summary of consolidated financial results for the first quarter of the year ended 31 Mar 2010 (unaudited): sales of major products: pharmaceuticals (overseas).
July 31, 2009... For its 1Q 2009 (period ends 30 Jun 2009), Dainippon Sumitomo Pharma has reported overseas product sales data: meropenem trihydrate Yen 5.5 bn (Yen 6.1 bn for its 1Q 2008), mosapride citrate Yen 0.3 bn (Yen 0.2 bn), and zonisamide Yen 0.1 bn...

Dainippon Sumitomo Pharma summary of consolidated financial results for the first quarter of the year ended 31 Mar 2010 (unaudited): development pipeline (as of 31 Jul 2009): major products under development in Japan by DSP.
July 31, 2009... Dainippon Sumitomo Pharma has reported on major products under development in Japan (as of 31 Jul 2009). NDA filed (miriplatin hydrate, metformin hydrochloride, and meropenem hydrate), Phase III (repaglinide, lurasidone), Phase II (ranirestat,...